WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017059813) ANTIBODY TO HEPATITIS B SURFACE ANTIGEN AND USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/059813    International Application No.:    PCT/CN2016/101560
Publication Date: 13.04.2017 International Filing Date: 09.10.2016
IPC:
C07K 16/10 (2006.01), C12N 15/13 (2006.01), C12N 15/63 (2006.01), C12N 5/10 (2006.01), A61K 39/395 (2006.01), A61P 31/14 (2006.01), A61P 1/16 (2006.01)
Applicants: XIAMEN UNIVERSITY [CN/CN]; No.422 Si Ming Nan Road, Siming District Xiamen, Fujian 361005 (CN).
YANG SHENG TANG COMPANY, LTD [CN/CN]; Jinniu Road, Jinpan Industrial Development Zone Haikou, Hainan 570216 (CN)
Inventors: LUO, Wenxin; (CN).
ZHOU, Bing; (CN).
ZHANG, Juan; (CN).
YUAN, Quan; (CN).
ZHANG, Tianying; (CN).
ZHANG, Jun; (CN).
XIA, Ningshao; (CN)
Agent: CCPIT PATENT AND TRADEMARK LAW OFFICE; 8th Floor, Vantone New World Plaza 2 Fuchengmenwai Street, Xicheng District Beijing 100037 (CN)
Priority Data:
201510647977.7 09.10.2015 CN
Title (EN) ANTIBODY TO HEPATITIS B SURFACE ANTIGEN AND USE THEREOF
(FR) ANTICORPS ANTI-ANTIGÈNE DE SURFACE D’HÉPATITE B ET SON UTILISATION
(ZH) 抗乙肝表面抗原的抗体及其用途
Abstract: front page image
(EN)Provided in the present invention are an antibody, in particular humanized antibody, to hepatitis B surface antigen (HBsAg), a nucleic acid molecule encoding the same, a preparation method therefor, and a pharmaceutical composition comprising the same. Also provided in the present invention are uses of the antibody and pharmaceutical composition. The antibody and pharmaceutical composition of the present invention can be used for prevention and/or treatment of HBV infection or diseases associated with HBV infection (such as hepatitis B), used for neutralizing HBV virulence in the body of a subject (such as human), or used for lowering the serum level of HBV DNA and/or HBsAg in the body of the subject.
(FR)La présente invention concerne un anticorps, en particulier un anticorps humanisé, anti-antigène de surface d'hépatite B (HBsAg), une molécule d'acide nucléique codant pour celui-ci, son procédé de préparation, et une composition pharmaceutique le comprenant. Des utilisations de l'anticorps et de la composition pharmaceutique sont en outre décrites. L'anticorps et la composition pharmaceutique selon la présente invention peuvent être utilisés pour prévenir et/ou traiter une infection par le VHB ou des maladies associées à une infection par le VHB (telles que l'hépatite B), pour neutraliser la virulence du VHB dans le corps d'un sujet (tel qu'un sujet humain), ou pour abaisser le taux sérique de l'ADN du VHB et/ou du HBsAg dans le corps du sujet.
(ZH)本发明提供了抗乙肝表面抗原(HBsAg)的抗体(特别是人源化抗体),编码它们的核酸分子,制备它们的方法,以及包含它们的药物组合物。本发明还提供所述抗体和药物组合物的用途。本发明的抗体和药物组合物可用于预防和/或治疗HBV感染或与HBV感染相关的疾病(例如乙肝),用于在受试者(例如人)体内中和HBV的毒力,或用于在受试者体内降低HBV DNA和/或HBsAg的血清水平。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)